Exploring Out-Licensing Deals for Innovative ADC Drugs from China
Chinese innovative drug companies are gradually setting their sights on overseas markets, and domestically developed innovative drugs are stepping into their golden age. Particularly, Antibody-Drug Conjugates (ADCs) have become a significant force for Chinese innovative drug companies to shine on the international stage.
According to publicly available information, as of January 2024, about 18 China-based companies have obtained out-licensing arrangements for 26 ADC-related products, with the disclosed total transaction amount exceeding $40 billion in US dollars. Licensing transactions on novel drugs have become another trend for Chinese biotech/pharma companies to cooperate with international life sciences organizations.
It's worth mentioning that among these 18 Chinese companies that have out-licensing deals for ADC pipelines, ChemExpress has established full collaboration, including technical services or the supply of intermediate products. We are dedicated to creating greater value for customers, maintaining close and good cooperative relationships with our customers.
ChemExpress is one of the early Chinese CDMO companies engaged in the production of ADCs and high potency active pharmaceutical ingredient, focusing on providing CMC & CDMO services for the small molecule chemical part of ADC drugs and customized ADC conjugation services. We have a substantial inventory of over 80 payloads and 400 linkers, in addition to extensive expertise in linker compound synthesis, with over 1,000 successful syntheses. Currently, we have 8 DMF-filed ADC small molecule products.
ChemExpress R&D team comprises over 230 professional researchers and has empowered more than 780 clients with support for their ADC research and development production projects, successfully assisting customers in completing over 30 CMC projects. We have collaborated with RemeGen to assist in the development and launching of RC48—the first ADC drug developed and approved in China. We are committed to accompanying and empowering our customers, deeply understanding their needs, and accelerating the empowerment of global partners to achieve the entire process from preclinical to commercial production.